A Clinical Review of Small-Cell Carcinoma of the Urinary Bladder

Thota, Swapna; Kistangari, Gaurav; Daw, Hamed; Spiro, Timothy

doi:10.1016/j.clgc.2012.11.002

Cited by 42 publications

(56 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SCBC commonly affects men (men/women ratio is 3.8:1 [3,6,7]) in their seventh or eighth decade of life [2], and the patient in our case was 58 years old.…”

Section: Discussionmentioning

confidence: 99%

“…A second view suggests the origin of SCBC from malignant transformation of neuroendocrine stem cells that are found within the urothelium and bladder [8]. The third hypothesis is that SCBC originates from extreme metaplasia of urothelial cells [2].…”

Section: Discussionmentioning

confidence: 99%

“…Neuroendocrine markers, such as chromogranin A, synaptophysin, CD56 and neuron specific enolase (NSE) are often focally or diffusely positive for these cancers by immunohistochemical methods [10]. However, the absence of staining for these markers does not rule out the diagnosis of SCBC, and diagnosis relies on microscopic findings [2]. The microscopic examination of our case showed a diffuse patternless type growth of loosely cohesive, relatively uniform, small round to oval cells with powdery (salt-and-pepper) nuclear chromatin and scant cytoplasm (Fig.…”

Section: Discussionmentioning

confidence: 99%

“…Treatment decisions are usually based on retrospective studies and case reports [2]. Because SCBC is more aggressive than the conventional ones, it should be treated as metastatic disease, even there is no radiologic evidence [1,3].…”

Section: Discussionmentioning

confidence: 99%

“…Bladder cancer (BC) is the fourth most common cancer in men but small-cell bladder cancer (SCBC) is a rare form and composes less than 1% of primary bladder malignancies [2].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

An Asymptomatic Small-Cell Bladder Cancer Until Bilateral Ureteral Obstruction Happened

Demir

2014

J Med Cases

View full text Add to dashboard Cite

Small-cell bladder cancer is a rare form and composes less than 1% of primary bladder malignancies. We present a case with a large small-cell bladder cancer leading to acute kidney failure clinic without gross hematuria. Computed tomography revealed that all the bladder walls were invaded by the extensive tumor and bilateral hydronephrosis. Double J stent for left side and nephrostomy tube for the right side were inserted, and bladder biopsy was taken by transurethral resection. Pathologic examination revealed small-cell bladder cancer. The patient did not accept chemotherapy. He died because of the acute renal failure 4 months later since the beginning.

show abstract

“…SCBC commonly affects men (men/women ratio is 3.8:1 [3,6,7]) in their seventh or eighth decade of life [2], and the patient in our case was 58 years old.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Bladder cancer (BC) is the fourth most common cancer in men but small-cell bladder cancer (SCBC) is a rare form and composes less than 1% of primary bladder malignancies [2].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

An Asymptomatic Small-Cell Bladder Cancer Until Bilateral Ureteral Obstruction Happened

Demir

2014

J Med Cases

View full text Add to dashboard Cite

show abstract

Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma

et al. 2015

View full text Add to dashboard Cite

To describe the clinical characteristics, treatment patterns and outcomes in advanced small cell bladder cancer (aSCBC) patients and compare to those with urothelial carcinoma (UC). Individuals in the National Cancer Data Base with a diagnosis of either nodal (TxN+M0) or distant metastatic (TxNxM1) disease were identified from 1998 to 2010. We assessed the relationships between stage, treatment modalities and survival in the aSCBC cohort and compared these to UC patients. In the 960 patient aSCBC cohort (62% M1), 50% received palliative therapy alone, 68% in M1 versus 21% in M0 groups (P < 0.0001). Single modality local therapy (15%) and surgical (21%) or radiation‐based (14%) multimodal therapy (MMT) were used in the other 50%. Cystectomy‐based MMT was utilized in 45% of N+M0 versus 6.4% of NxM1 patients (P < 0.0001). Median overall survival (OS) for aSCBC patients was 8.6 months; 13.0 months in N+M0 versus 5.3 months in NxM1 patients (P < 0.0001). Survival was similar between TxN1M0 and TxN2‐3M0 patients (14.8 months vs. 12.1 months, P = 0.15). Urothelial carcinoma patients (n = 27,796, 45% M1) lived longer compared to aSCBC patients in the N+M0 group (17.3 months vs. 13.0 months, P = 0.0007). There were not clinically significant differences in OS between UC and aSCBC patients in the M1 group. Advanced SCBC is a rare disease with a poor survival and palliative therapy is common, especially in M1 patients. In comparison to UC, the outcomes for aSCBC patients are worse in those with lymph node only involvement but similar in those with distant disease.

show abstract